New drug lebrikizumab put to the test in healthy chinese participants
NCT ID NCT06243198
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested the safety and tolerability of a single dose of lebrikizumab in 24 healthy Chinese adults. Half received the drug and half received a placebo, with researchers monitoring side effects and how the drug enters and leaves the body. The study is complete and provides basic safety data for this drug in a Chinese population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lebrikizumab
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China